Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment

Urologic Oncology
Shalini S YadavAshutosh K Tewari

Abstract

Next-generation sequencing (NGS) of the genetic information of cancer cells has revolutionized the field of cancer biology, including prostate cancer (PCa). New recurrent alterations have been identified in PCa (e.g., TMPRSS2-ERG translocation, SPOP and CHD1 mutations, and chromoplexy), and many previous ones in well-established pathways have been validated (e.g., androgen receptor overexpression and mutations; PTEN, RB1, and TP53 loss/mutations). With its highly heterogeneous nature, PCa continues to pose a tremendous challenge in terms of diagnosis and prognosis. Combining the information gained through NGS studies with clinicopathological and radiological data will help diagnose the aggressiveness of the cancer with greater accuracy. Furthermore, understanding the heterogeneity of tumor through single-cell or single-molecule sequencing technology will also strengthen the prognosis and provide better, patient-specific drug identification. As this research becomes more prominent, it is important that urologic oncologists become familiar with the various NGS technologies and the results generated using them. We highlight the commonly used NGS tools and summarize recent discoveries relevant to PCa.

References

Aug 15, 2003·Molecular and Cellular Biology·Aurelian RaduMaria-Magdalena Georgescu
Dec 9, 2003·The Journal of Clinical Investigation·David BernardDavid H Beach
Oct 29, 2005·Science·Scott A TomlinsArul M Chinnaiyan
Jun 3, 2006·Cancer Research·Raanan BergerMassimo Loda
Jun 19, 2008·Differentiation; Research in Biological Diversity·Cory Abate-ShenEdward Gelmann
Oct 11, 2008·Nature Biotechnology·Jeffery A Schloss
Oct 11, 2008·Nature Biotechnology·Daniel BrantonJeffery A Schloss
Feb 5, 2009·Cancer Research·Anuradha GopalanWilliam L Gerald
Jun 8, 2010·Nature Medicine·Nallasivam PalanisamyArul M Chinnaiyan
Jun 22, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Samson W FineVictor E Reuter
Jun 29, 2010·Cancer Cell·Barry S TaylorWilliam L Gerald
Sep 21, 2010·Nature Biotechnology·Christoph BockAlexander Meissner
Nov 26, 2010·The Journal of Clinical Investigation·Ankur SharmaKaren E Knudsen
Mar 4, 2011·Science Translational Medicine·Bushra AteeqArul M Chinnaiyan
Apr 19, 2011·Briefings in Bioinformatics·Zhide Fang, Xiangqin Cui
Aug 5, 2011·Science Translational Medicine·Scott A TomlinsArul M Chinnaiyan
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A RubinArul M Chinnaiyan
Sep 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A MertzRobert J Sims
Dec 3, 2011·Science Translational Medicine·Sameek RoychowdhuryArul M Chinnaiyan
Jan 13, 2012·The New England Journal of Medicine·Charles M EwingKathleen A Cooney
Jan 24, 2012·Cell·Christopher A Maher, Richard K Wilson
Mar 20, 2012·The Journal of Urology·Patrick C Walsh
Mar 21, 2012·Nature Immunology·Laurence ZitvogelGuido Kroemer
May 23, 2012·Nature Genetics·Christopher E BarbieriLevi A Garraway
Jun 1, 2012·Science Translational Medicine·Tim ForshewNitzan Rosenfeld
Jul 13, 2012·Scientific Reports·Takahito OhshiroTomoji Kawai
Dec 14, 2012·Proceedings of the National Academy of Sciences of the United States of America·Wei QiEn Li
Dec 26, 2012·European Urology·Johan LindbergHenrik Grönberg
Mar 13, 2013·Current Opinion in Urology·Michael J Donovan, Carlos Cordon-Cardo
Mar 16, 2013·Cancer Research·Lia BurkhardtRonald Simon

❮ Previous
Next ❯

Citations

Feb 16, 2016·Genomics, Proteomics & Bioinformatics·Pingjian Yu, Wei Lin
May 29, 2019·Asian Journal of Andrology·Shi-Dong LvWen-Hua Huang
Jul 26, 2016·Genomics & Informatics·Sangmoon Lee, Murim Choi
Jul 12, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Yamin WangZhong Chen
Jun 3, 2016·Oncotarget·Faheem Ahmed KhanZhang ShuJun
May 16, 2018·Academic Pathology·Yuriy O AlekseyevDaniel Remick
Jul 8, 2017·BioMed Research International·Andrés López-CortésCésar Paz-Y-Miño
Nov 12, 2020·Nature Reviews. Urology·Arjanneke F van de MerbelGabri van der Pluijm
Apr 9, 2020·Protein and Peptide Letters·Fatima AkramMuhammad Shrafat Ali
Aug 20, 2021·Journal of Maxillofacial and Oral Surgery·S Vinod NairRavindran Ankathil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.